Reagent and Library Prep Kit Bundles Available for the MiniSeq System

Order your MiniSeq reagents and library prep kits together for additional savings and convenience. Select item 20005610 and add to your cart.

TruSight Tumor 15

Focused sequencing panel to assess 15 genes that are commonly mutated in solid tumors in a single assay, with a simple, rapid workflow.Read More...

TruSight Tumor 15 MiSeq Kit


TruSight Tumor 15 (Library Prep Only)


TruSight Tumor 15 MiniSeq Kit


Product Highlights

TruSight Tumor 15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. It accurately detects low-frequency variants from 20 ng of starting DNA and is optimized for formalin-fixed, paraffin-embedded (FFPE) tumor tissue.

View the Gene List

Featuring a rapid workflow that can be easily integrated into lab procedures, this panel offers a single assay for accurate, economical, and rapid analysis of solid tumors.

This TruSight Tumor panel offers:

  • Comprehensive workflow: Assess 15 genes with one simple workflow instead of single, iterative gene testing with polymerase chain reaction (PCR)
  • Efficient: Rapid turnaround with only 3.5 hours of hands-on time, going from DNA to data in approximately 36 hours
  • Relevant gene content for solid tumors: Somatic variants selected from relevant industry guidelines1,2, key opinion leaders3,4, and pharmaceutical research
  • Sensitive variant detection from low DNA input: Accurate somatic variant detection of 5% allele frequency using 20 ng DNA from FFPE tissue samples
TruSight Tumor 15 Sample Datasets

3 human reference samples and 5 FFPE-exacted DNA samples from lung, colon, melanoma, and breast tumors were prepared using TruSight Tumor 15. These libraries were sequenced on the MiniSeq System using a high output kit at a 2 x 150 bp read length configuration with dual indexing. The total yield was 7.6 Gb with 94.9% of bases at or above Q30.

Browse the data in BaseSpace Sequence Hub:

Access to this data requires a BaseSpace Sequence Hub login.
Register for BaseSpace Sequence Hub

See All Cancer Research Panels

Frequently Purchased Together



仪器 推荐的样本数 读长
MiniSeq System 每次运行的样本:中通量:2–3,高通量:8(基于93.5%的碱基覆盖度≥500倍) 2 × 150 bp (最大推荐值)
MiSeq System 每次运行8个样本(v3试剂,基于93.5%的碱基覆盖度≥500倍) 2 × 151 bp (最大推荐值)


TruSight Tumor 15 AmpliSeq for Illumina Focus Panel AmpliSeq for Illumina Comprehensive Panel v3 AmpliSeq for Illumina Cancer Hotspot Panel v2 TruSight Tumor 170
变异种类 体细胞变异, 插入缺失 单核苷酸多态性(SNP), 基因融合, 体细胞变异, 拷贝数变异(CNV), 插入缺失 单核苷酸多态性(SNP), 基因融合, 体细胞变异, 拷贝数变异(CNV), 插入缺失 插入缺失, 体细胞变异, 单核苷酸多态性(SNP) 基因融合, 插入缺失, 单核苷酸多态性(SNP), 结构变异, 拷贝数变异(CNV), 体细胞变异
技术 测序 测序 测序 测序 测序
方法 扩增子测序 , 靶向DNA测序 靶向DNA测序 , 靶向RNA测序 , 扩增子测序 靶向DNA测序 , 靶向RNA测序 , 扩增子测序 靶向DNA测序 , 扩增子测序 靶向RNA测序 , 靶向DNA测序
物种类别 人类 人类 人类 人类 人类
特殊的样本类型 FFPE组织 血液, FFPE组织 血液, FFPE组织 血液, FFPE组织 低起始量样本, FFPE组织
癌症类型 实体瘤 实体瘤 实体瘤 泛癌, 实体瘤 实体瘤
系统兼容性 MiniSeq , 研究模式下的MiSeqDx , MiSeq , MiSeq MiniSeq , MiSeq , MiSeq, 研究模式下的MiSeqDx NextSeq 550 研究模式下的MiSeqDx , MiniSeq , MiSeq , MiSeq NextSeq 550 , NextSeq 500 , HiSeq 2500

Method-Specific Workflow Example

TruSight Tumor 15 Gene List

Kit requires MiSeq Software v2.6 or higher and the Illumina Annotation Engine. Download files

Related Products

AmpliSeq for Illumina Focus Panel

Targeted DNA and RNA research panel investigating 52 genes with known relevance to solid tumors.

AmpliSeq for Illumina Custom DNA Panel

Targeted custom research panels optimized for sequencing specific targets or genomic content of interest.

TruSight RNA Pan-Cancer

Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and formalin-fixed, paraffin-embedded (FFPE) tissue.

  1. NCCN Clinical Practice Guidelines in Oncology Accessed 15 June 2015.
  2. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D; ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1-9.
  3. Rousseau B, Jacquot C, Le Palabe J, et al. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in non-small cell lung cancer treatment. Sci Rep. 2015;5:10356.
  4. Haley L, Tseng LH, Zheng G, et al. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers [published online July 31 2015]. Mod Pathol. 2015. doi: 10.1038/modpathol.2015.86.